3:52 PM
 | 
Feb 24, 2017
 |  BC Extra  |  Company News

Xynomic licenses AbbVie’s abexinostat

Xynomic Pharmaceuticals Inc. (Cheyenne, Wyo.) said it gained exclusive, worldwide rights to develop and commercialize oncology candidate abexinostat from AbbVie Inc. (NYSE:ABBV). Xynomic said it plans to...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >